Collaborative ABA Services, LLC has launched the initial rollout of CollabWait, a cloud-based application designed to ...
Horizon Recovery Confirms Ongoing Clinical Operations for Teen Rehabs in Arizona BUCKEYE, AZ, UNITED STATES, January 7, ...
University of Utah alum, Esti, found hope and purpose through Huntsman Mental Health Institute’s Intensive Outpatient Program ...
The FDA has accepted an investigational new drug application for an investigational and proprietary combination therapy to ...
Everyday Health on MSN
We tested over 65 online therapy companies — these 11 were the most affordable we actually would recommend
After testing over 65 therapy services to find the best options, we believe these 11 most affordable online therapy services ...
Oct 3 (Reuters) - Rocket Pharmaceuticals (RCKT.O), opens new tab said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder.
Having already altered the journey of its rare disease gene therapy to a hoped-for FDA approval, Rocket Pharmaceuticals has now aborted the mission entirely. The biotech initiated a rolling biologics ...
Like all variants of cognitive behavioral therapy, cognitive behavioral therapy for psychosis (CBTp) is a short-term, structured form of psychotherapy based on the idea that the way someone thinks ...
Scientists report the first therapy to slow the deadly brain disease. A one-time gene therapy treatment has shown remarkable success in slowing the progression of Huntington's disease in a preliminary ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Please provide your email address to receive an email when new articles are posted on . This is the first biologics license application submitted for a gene-agnostic retinal disease gene therapy.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback